[
  {
    "ts": null,
    "headline": "The Analyst Verdict: Moderna In The Eyes Of 9 Experts",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=550f73adf92b10906debaabb4985cf9a3cd88fd4c5e3cdc11cf963079cd236ff",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771340479,
      "headline": "The Analyst Verdict: Moderna In The Eyes Of 9 Experts",
      "id": 139134753,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/analyst_ratings_4.jpg?width=2048&height=1536",
      "related": "MRNA",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=550f73adf92b10906debaabb4985cf9a3cd88fd4c5e3cdc11cf963079cd236ff"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $41",
    "summary": "Goldman Sachs  analyst Salveen Richter   maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $36 to $41.",
    "url": "https://finnhub.io/api/news?id=cbaaa7562ec6da0dc2045e57c87c51c801363c51daff7fbb947a33109f2f0d1b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771336655,
      "headline": "Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $41",
      "id": 139134754,
      "image": "",
      "related": "MRNA",
      "source": "Benzinga",
      "summary": "Goldman Sachs  analyst Salveen Richter   maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $36 to $41.",
      "url": "https://finnhub.io/api/news?id=cbaaa7562ec6da0dc2045e57c87c51c801363c51daff7fbb947a33109f2f0d1b"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Maintains Sector Perform on Moderna, Raises Price Target to $30",
    "summary": "RBC Capital  analyst Luca Issi   maintains Moderna (NASDAQ:MRNA) with a Sector Perform and raises the price target from $25 to $30.",
    "url": "https://finnhub.io/api/news?id=2f1fee266a0089249fde5525d88d6eeb73dcc7d44a79586f9cec26a865ab4380",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771334140,
      "headline": "RBC Capital Maintains Sector Perform on Moderna, Raises Price Target to $30",
      "id": 139134755,
      "image": "",
      "related": "MRNA",
      "source": "Benzinga",
      "summary": "RBC Capital  analyst Luca Issi   maintains Moderna (NASDAQ:MRNA) with a Sector Perform and raises the price target from $25 to $30.",
      "url": "https://finnhub.io/api/news?id=2f1fee266a0089249fde5525d88d6eeb73dcc7d44a79586f9cec26a865ab4380"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE",
    "summary": "mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA / ACCESS Newswire / February 17, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...",
    "url": "https://finnhub.io/api/news?id=45988e750e909376863700dd9513ec48cf5357ee85992535b0901381f5d69f30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771329600,
      "headline": "Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE",
      "id": 139121420,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA / ACCESS Newswire / February 17, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...",
      "url": "https://finnhub.io/api/news?id=45988e750e909376863700dd9513ec48cf5357ee85992535b0901381f5d69f30"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Stock Rises After EU Marketing Authorization For mNEXSPIKE",
    "summary": "Moderna shares are trading higher Tuesday after the company announced European Commission marketing authorization for its COVID-19 vaccine, mNEXSPIKE.",
    "url": "https://finnhub.io/api/news?id=79bc7daba30791cbdc9f5483442d3384b89501cd4767363e9346eb88bd48f3d7",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771328574,
      "headline": "Moderna Stock Rises After EU Marketing Authorization For mNEXSPIKE",
      "id": 139134756,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/17/Moderna--Inc-.jpeg?width=2048&height=1536",
      "related": "MRNA",
      "source": "Benzinga",
      "summary": "Moderna shares are trading higher Tuesday after the company announced European Commission marketing authorization for its COVID-19 vaccine, mNEXSPIKE.",
      "url": "https://finnhub.io/api/news?id=79bc7daba30791cbdc9f5483442d3384b89501cd4767363e9346eb88bd48f3d7"
    }
  },
  {
    "ts": null,
    "headline": "Evercore ISI Group Maintains In-Line on Moderna, Raises Price Target to $35",
    "summary": "Evercore ISI Group  analyst Cory Kasimov   maintains Moderna (NASDAQ:MRNA) with a In-Line and raises the price target from $28 to $35.",
    "url": "https://finnhub.io/api/news?id=bb40687f65211e8d5bddfaf4b8466b2091bb46f31cbe8ba5c11ae3d45202c51b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771325308,
      "headline": "Evercore ISI Group Maintains In-Line on Moderna, Raises Price Target to $35",
      "id": 139134757,
      "image": "",
      "related": "MRNA",
      "source": "Benzinga",
      "summary": "Evercore ISI Group  analyst Cory Kasimov   maintains Moderna (NASDAQ:MRNA) with a In-Line and raises the price target from $28 to $35.",
      "url": "https://finnhub.io/api/news?id=bb40687f65211e8d5bddfaf4b8466b2091bb46f31cbe8ba5c11ae3d45202c51b"
    }
  },
  {
    "ts": null,
    "headline": "The European Commission Approves Moderna's mNEXSPIKE (mRNA-1283), A New Covid Vaccine, For Active Immunization To Prevent Covid-19 In Individuals Aged 12 Years And Older",
    "summary": "This marketing authorization follows the positive opinion adopted by the European Medicines Agency&#39;s (EMA) Committee for Medicinal Products for Human Use (CHMP) and marks Moderna&#39;s third product authorized in the",
    "url": "https://finnhub.io/api/news?id=11fa0f2cf96498844d12ba88bab15f3cf45839c461842bf97ebaf8eb70147d8c",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771315848,
      "headline": "The European Commission Approves Moderna's mNEXSPIKE (mRNA-1283), A New Covid Vaccine, For Active Immunization To Prevent Covid-19 In Individuals Aged 12 Years And Older",
      "id": 139123231,
      "image": "",
      "related": "MRNA",
      "source": "Benzinga",
      "summary": "This marketing authorization follows the positive opinion adopted by the European Medicines Agency&#39;s (EMA) Committee for Medicinal Products for Human Use (CHMP) and marks Moderna&#39;s third product authorized in the",
      "url": "https://finnhub.io/api/news?id=11fa0f2cf96498844d12ba88bab15f3cf45839c461842bf97ebaf8eb70147d8c"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Secures Third EU-Authorized Vaccine With mNEXSPIKE, Supporting Protection Against Endemic COVID-19 As European Market Reopens In 2026",
    "summary": "mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company&#39;s respiratory vaccine portfolio in Europe",
    "url": "https://finnhub.io/api/news?id=f671a5c4fce8c10fb9cee8795409642f35c7be69bedab73bfe6c5f8bfe66c4dc",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771315780,
      "headline": "Moderna Secures Third EU-Authorized Vaccine With mNEXSPIKE, Supporting Protection Against Endemic COVID-19 As European Market Reopens In 2026",
      "id": 139123232,
      "image": "",
      "related": "MRNA",
      "source": "Benzinga",
      "summary": "mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company&#39;s respiratory vaccine portfolio in Europe",
      "url": "https://finnhub.io/api/news?id=f671a5c4fce8c10fb9cee8795409642f35c7be69bedab73bfe6c5f8bfe66c4dc"
    }
  }
]